InterAx Biotech
Curated by SignalArrestin-based biosensors and computational methods for GPCR based drug discovery
Overview
InterAx Biotech is a spin-off from ETH Zurich that uses mutated arrestins as novel biosensors and has a computational platform for analysis. They have a combination of proprietary arrestin-based biosensors and computational methods which allow for quantitative comparison of drug-induced GPCR signalling pathways. This helps the identification of not just the GPCR reaction with the drug, but also if the reaction is beneficial or adverse. The company develops and sells drug screening packages which help in selecting drug candidates, quantifying cellular responses and in predicting drug action. The company offers two main product lines of Arrestin mutants (with biosensor applications) for in-vitro assays and cellular assays. The company also offers image analysis services mainly for fluorescence microscopy images which help in detecting, delineating and quantifying subcellular structures. The company is supported by the Paul Scherer Institute and a finalist of the Swiss Innovation Challenge.
Key facts
- Founded
- 2014
- Headquarters
- Villigen, Switzerland
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Contact
- Primary office
- Sign up to view
- Sign up to view